Skip to main content
  • Home
  • News
  • Myasthenia Alliance Australia PBAC Submission Update Webinar

Myasthenia Alliance Australia PBAC Submission Update Webinar

Myasthenia Alliance Australia PBAC Submission Update Webinar

Posted on Thursday, October 03 2024

The Myasthenia Alliance Australia (MAA) Board invite the Myasthenia community of Australia to join the following webinar. 

The Board thanks Alexion for facilitating this opportunity to understand more about the processes involved in achieving new treatment options.

You are invited to a Zoom webinar on Friday 11 October at 12pm (daylight saving time) to hear from the Alexion team about the recent Pharmaceutical Benefits Advisory Committee (PBAC) Submission outcome and to learn a bit more about the process itself.

They will also share some information about ongoing advocacy that may be of interest.

When you join the webinar, you will not be on camera and your microphone will be on mute.

You are invited to ask questions after the presentations via the Q&A chat.

We will ask you to complete a short, anonymous survey at the end of the session to gather your feedback.

YOUR PRIVACY IS IMPORTANT TO US

We will not be recording the session nor collecting any personal or digital information from individuals who join the webinar.

When: Oct 11, 2024 12:00 PM Canberra, Melbourne, Sydney (please note if you are in Queensland it will begin at 11am)

Topic: Myasthenia Alliance Australia PBAC Submission Update Webinar

Click on this link below to join: https://alexion.zoom.us/j/97472163550?pwd=lJrdbJIOlqsBU05Pf6qGoc6Ve9tbUQ.z8uFjrpt0cZ9cgGH

Passcode: 830454

Or Telephone:

Dial (for higher quality, dial a number based on your current location):

+61 2 8015 6011 Australia
+61 3 7018 2005 Australia
+61 7 3185 3730 Australia
+61 8 6119 3900 Australia
+61 8 7150 1149 Australia

We look forward to seeing you at the Webinar!

MessaGes Mailing List

Enter your details below to receive our monthly MessaGes Newsletter and upcoming News and Events directly to your Email inbox.